BridgeBio Pharma vs Insmed
BBIO and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and INSM compare
Insmed is the larger company, worth 1.7 times as much as BridgeBio Pharma ($24.6B against $14.7B).
Insmed grew revenue faster over the last twelve months (240% versus 167% for BridgeBio Pharma).
Insmed scores higher on the StockData Score (8 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | INSM |
|---|---|---|
| Size and price | ||
| Market cap | $14.7B | $24.6B |
| Share price | $74.95 | $112.58 |
| Change, 1 year | 12.5% | −32.6% |
| Change, 5 years | 40.3% | 237% |
| Beta (5Y) | 1.13 | 0.79 |
| Employees | 834 | 1,664 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.5× (better) | 16.2× |
| P/B | – | 33.9× |
| FCF yield | −2.5% (better) | −2.6% |
| Fair value | – | $61.67 |
| Margin of safety | – | −82.5% |
| Growth | ||
| Revenue growth (TTM) | 167% | 240% (better) |
| Revenue growth, 5Y average | 127% (better) | 29.8% |
| Profitability | ||
| Gross margin | 94.3% (better) | 84.4% |
| Operating margin | −38.5% | −37.1% (better) |
| Net margin | – | −39.9% |
| FCF margin | −39.1% (better) | −41.3% |
| Return on equity | – | −72.5% |
| Financial health | ||
| Debt / equity | – | 0.76 |
| Interest coverage | −7.1× | −6.9× (better) |
| Current ratio | 2.09 | 2.86 (better) |
| Altman Z-score | 0.06 | 6.56 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.1% | 103% |
| Held by insiders | 35.5% | 0.88% |
| Insider net buying, 12 months | −$105M (better) | −$167M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 15.6% | 6.4% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- INSM stock overview
- INSM income statement
- INSM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.